Clinical trial

Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria

NCT02619929

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2016-02-01

PhaseN/A

Study timeline

Study start (actual)2016-02-01Date precision: month

Registry last updated2018-08-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small-Cell Lung Cancerunresolved

Breast Cancerunresolved

Interventions

Vinorelbine oralDRUG

Sponsors & collaborators

Pierre Fabre Pharma GmbHlead sponsor

Winicker Norimed GmbHcollaborator

Mapped research locations

BerlinGermany1 ViennaAustria1 HanoverGermany1 CologneGermany1 MainzGermany1 MünsterGermany1 GrazAustria1 MannheimGermany1 LübeckGermany1 InnsbruckAustria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02619929 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.